Study Comparing Patritumab Deruxtecan to Standard Chemotherapy in Advanced EGFR-Mutated Lung Cancer

Inclusion Criteria

• Adults aged 18 or older.
• Diagnosed with advanced non-small cell lung cancer (NSCLC) that cannot be treated with surgery or radiation.
• Have a specific mutation in the EGFR gene (exon 19 deletion or L858R).
• Previously treated with one or two EGFR-targeted therapies, including a third-generation EGFR TKI.
• No other prior treatments for advanced NSCLC, such as chemotherapy or immunotherapy.
• Cancer has progressed while on or after third-generation EGFR TKI treatment.
• At least one tumor that can be measured by scans.
• Willing to provide a tumor sample for testing.
• Good overall health with an ECOG performance status of 0 or 1.
• Adequate blood cell counts and organ function based on recent lab tests.

Exclusion Criteria

• History of small cell lung cancer or squamous NSCLC.
• History of lung diseases like interstitial lung disease or radiation pneumonitis.
• Severe breathing problems due to lung conditions.
• Currently taking high doses of steroids or other immune-suppressing drugs.
• History of cancer spreading to the brain or spinal cord that is not well controlled.
• Previous treatment with drugs similar to Patritumab Deruxtecan.
• History of other cancers within the last 3 years, except for certain skin or cervical cancers.
• Uncontrolled heart disease.
• Active hepatitis B or C infection.
• Uncontrolled HIV infection.
• Significant eye disease affecting the cornea.